A REAL WORLD EVIDENCE MODEL TO COMPARE DIRECT ORAL ANTICOAGULANTS SAFETY OUTCOMES FOR ATRIAL FIBRILLATION PATIENTS IN SPAIN
Author(s)
Malé N, Solé A, Schoenherr N
Boehringer Ingelheim España S.A., Sant Cugat del Vallès, Spain
Presentation Documents
OBJECTIVES: In the last 10 years, different treatments for stroke prevention in atrial fibrillation (SPAF) have been launched in Spain. However, little is known about clinical outcomes and cost associated to patient events in real world practice. The aim of this model is to assist in the decision making of treatment selection based on the risk of a patient having an event. METHODS: The health outcomes model is based in five Real World Evidence (RWE) studies published in 2016. Safety outcomes data has been standardized for the population older than 40 years old. It allows data extrapolation for Spanish SPAF regional citizenry. The model compares real world clinical results and associated cost of various Direct Oral Anticoagulants (DOACs), adjusted to selected population (national, regional, provinces and healthcare areas). Population data was obtained from Statistics National Institute and two published Spanish studies, market share was provided for IMS and cost per event was according to DRG (Diagnostic Related Groups). RESULTS: This model provides an estimate number of patients having clinical events, such as thromboembolic ictus, mortality, intracranial, serious extracranial, gastrointestinal and serious hemorrhage or other hemorrhages, in the selected Spanish population. According to the model and on a national scale, 1.492 and 266 SPAF patients could have been spared serious hemorrhagic events with dabigatran compared to rivaroxaban and apixaban. Annual costs associated with these events were also calculated (excluding mortality). Potential annual cost-savings for the National Health System (NHS) amounted to 1.031.838€ (dabigatran vs apixaban) and 5.784.770€ (dabigatran vs rivaroxaban). CONCLUSIONS: According to the RWE model, appropriate DOAC treatment selection is important to decrease the number of patients having events and it also could generate potential savings for the Spanish NHS.
Conference/Value in Health Info
2017-11, ISPOR Europe 2017, Glasgow, Scotland
Value in Health, Vol. 20, No. 9 (October 2017)
Code
PCV33
Topic
Epidemiology & Public Health
Topic Subcategory
Safety & Pharmacoepidemiology
Disease
Cardiovascular Disorders